Migraine treatment Zolmitriptan launched by Actavis in Europe
Actavis Group today announced the launch of Zolmitriptan tablets immediately after the patents expired in a number of European countries.
Used to treat severe migraine headaches, Zolmitriptan Actavis is the generic equivalent of the brand product Zomig® from AstraZeneca.
Actavis launched Zolmitriptan immediately after the patents expired. The Company’s conventional film coated tablets were first to market in the UK, France, Italy, Denmark, Norway and Sweden and also launched in Finland.
At the same time, Zolmitriptan Actavis orodispersible tablets (ODT) were first to market in the UK, France, Netherlands, Ireland, Denmark, Norway and Sweden. The product was also brought to market in Finland.
Actavis had already marketed Zolmitriptan ODT in a number of countries including Malta, Romania and Ukraine. Zolmitriptan Actavis is produced at the Company’s manufacturing site in Malta.
According to IMS, Zolmitriptan conventional and ODT branded sales in Europe were about EUR117m in 2011.
This news content was configured by WebWire editorial staff. Linking is permitted.